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1,2
Chemotherapy dose intensification with the help of hemWe report a case of metastatic gastrointestinal leiomyosarcoma treated with high-dose combination chemoatopoietic growth factors has been employed in various histological subsets of sarcomas; improved response rates with therapy and autologous peripheral blood stem cell transplantation. After incomplete surgical resection, moderate and variable increases in response and survival were observed. 1 High-dose chemotherapy (HDC) and autoenteral, peritoneal and hepatic involvement remained. Postoperatively, standard-dose chemotherapy with etologous peripheral blood stem cell transplantation (PBSCT) has produced similarly inconclusive results. 4,5 HDC and poside, ifosfamide, cisplatin and epirubicine, and highdose chemotherapy with the same agents (carboplatin PBSCT have been used infrequently in the treatment of STS and their role in the adjuvant, neoadjuvant and pallireplacing cisplatin) was given. Treatment was well tolerated and the patient remains in complete remission at ative treatment of these malignancies remains to be defined. The activity of high-dose ifosfamide with and without 36+ months. We conclude that high-dose chemotherapy followed by autologous peripheral blood stem cell transconcomitant dose escalation of anthracyclines has been demonstrated in locally advanced and metastastic sarcomas. plantation may be of use as treatment for inoperable residual disease after resection of the primary lesion in Its use in stage IV patients, however, has remained palliative and toxic, resulting in median remission durations of gastrointestinal and other soft tissue sarcomas. Keywords: gastrointestinal sarcoma; leiomyosarcoma; under 12 months.
1,5
When confronted with the question of how to treat a soft tissue sarcoma; high-dose chemotherapy; autologous peripheral blood stem cell transplantation patient with metastatic gastric leiomyosarcoma we therefore decided against this palliative single-agent strategy. Attempting to maximize therapeutic efficacy while minimizing treatment toxicity, we chose a HDC regimen conStandard treatment modalities of soft tissue sarcomas (STS) sisting of etoposide, ifosfamide, carboplatin, and epirubicin include surgery, radiation and chemotherapy.
1 Due to the (VIC-E) that had demonstrated significant activity in small toxicity of radiation therapy in the abdominal cavity, treatcell lung cancer and other solid tumors, 6 and combines ment of gastrointestinal STS is restricted to surgery and three active agents in sarcoma chemotherapy plus chemotherapy in most cases.
2 Long-term disease-free surcis/carboplatin with PBSCT for hematopoietic rescue. vival has been achieved almost exclusively in patients
In our view, the antisarcoma activity of the agents used whose tumors are amenable to curative resection.
1,2 Howin this protocol, 1,3,4 and improvements in supportive care ever, even with complete surgical resection, local and disleading to reduced morbidity and mortality made HDC and tant relapse of gastrointestinal STS occurs in 18-72% of PBSCT an acceptable option for experimental post-operatcases, depending on histological and other risk factors.
1,2 ive chemotherapy in our individual patient. To our knowl-A recent meta-analysis suggested a favorable influence of edge, the use of high-dose VIC-E followed by PBSCT in adjuvant conventional-dose chemotherapy after complete STS has only been described in a report by our group on macroscopic excision; however, further investigations will a successful case of neoadjuvant HDC in a patient with be necessary to define subsets of STS patients likely to primary inoperable liposarcoma.
1994, for diagnostic and palliative purposes, during which plete resection and in the presence of aggressive histologies. 2 The authors of the survey propose that patients the stomach was mobilized from pancreas, spleen and transverse colon to allow for a palliative R-2 resection.
falling in this category should be considered candidates for investigational adjuvant or adjunctive therapies.
2
Inoperable residual involvement of the proximal and distal anastomotic sites, peritoneum and liver was proven by Our case history demonstrates the feasibility of VIC-E HDC with PBSCT as adjunctive treatment of gastric leiintraoperative biopsy.
Pathological examination of the surgical specimens demomyosarcoma after incomplete resection. Treatment efficacy is indirectly suggested by the continued absence of onstrated a high-grade gastral leiomyosarcoma with involvement of proximal and distant surgical margins, perresidual or recurrent abdominal or distant metastases. Of course, we cannot exclude that either the conventional dose itoneum and liver. All findings were confirmed by an external reference pathologist. The patient was referred to our VIP-E chemotherapy or the high-dose ifosfamide component of VIC-E was responsible for the disease-free survival institution for further therapy.
Staging examinations showed no evidence of extraof our patient. Indeed, even biological factors, such as the dependence of the metastatic tumor tissue on growthabdominal lesions; however, distant micrometastases undetectable by current staging techniques could have occurred promoting factors produced by the primary bulk tumor may have influenced the current favorable outcome. during hematogenous dissemination.
2 Due to the small size of the intra-abdominal sarcomatous lesions (Ͻ1.0 cm), However, in a clinical situation for which no established curative treatments were available in March 1994, and where computed tomography scans failed to demonstrate the metastases documented by intraoperative pathology. In the evidence for reliable adjunctive conventional-dose chemotherapy regimens was scarce at best, our decision to utilize absence of radiological parameters, endoscopic examination and biopsy of involved anastomotic sites were used VIC-E HDC as investigational therapy in the case of unresectable gastrointestinal STS may not have been wrong. for primary response control.
Pre-operative chemotherapy had not been considered by We therefore cannot exclude that VIC-E HDC may be a potentially curative treatment option for eradication of the previous care givers. Additional surgical therapy was not possible. Radiation therapy was not feasible because residual systemic disease after incomplete surgical resection of gastrointestinal leiomyosarcomas. Comparison of the involved structures cannot tolerate effective doses of percutaneous irradiation. Thus, the only remaining treatthe utility of this or other HDC protocols with standarddose chemotherapy in this setting may be warranted in light ment option was adjunctive chemotherapy. For the abovementioned reasons, we opted to treat the patient with HDC of the moderate success of currently established adjuvant or adjunctive regimens. HDC was given in June 1994 at a cumulative dose of 193-201. etoposide (1500 mg/m 2 ), ifosfamide (12 000 mg/m 2 ), car- infrequently. 1,2 Except for a case report from the pediatric
